Physician profile

Melanie Frederick

Family Medicine · Shreveport, LA

NPI 1720062235

$2,983.26

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $559.02 2019-2020
Merck Sharp & Dohme LLC $375.66 2019-2021
Amarin Pharma, INC. $245.33 2019-2020
Pfizer INC. $243.07 2019-2021
Novo Nordisk INC $239.57 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $208.31 2019-2021
Glaxosmithkline, LLC. $141.57 2019-2020
Allergan, INC. $133.60 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $127.92 2019-2021
Lilly USA, LLC $123.12 2019-2021
Sanofi-Aventis U.S. LLC $113.60 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $83.97 2019-2020
Amgen INC. $73.39 2019
Kowa Pharmaceuticals America, INC. $61.90 2019-2021
Janssen Pharmaceuticals, INC $52.68 2019-2020
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Shire North American Group INC $51.32 2019
Daiichi Sankyo INC. $49.84 2019-2021
Avanir Pharmaceuticals, INC. $28.73 2019
Astellas Pharma US INC $26.60 2019-2021
Abbvie INC. $26.50 2021
Abbott Laboratories $17.56 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Melanie Frederick

$2,983.26

in general payments reported 2019-2025

Years
2019-2021
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/78257/melanie-frederick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.